[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353356-105":59,"doc-detail-353356-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","artificial-intelligence-for-molecular-biomarker-identification-in-gastrointestinal-and-hepatobiliary-cancers","Artificial Intelligence for Molecular Biomarker Identification in Gastrointestinal and Hepatobiliary Cancers","","Artificial intelligence (AI) has emerged as a promising tool for inferring molecular biomarkers directly from digitized histopathologic slides, yet evidence across gastrointestinal and hepatobiliary cancers is fragmented by tumor type and biomarker category. Studies were systematically identified using PRISMA 2020 and searched in PubMed, Embase, Web of Science, Scopus, and IEEE Xplore from 1 January 2015 to the search date. From 110 included studies, targets frequently included MSI, mutation status, molecular subtypes, and tumor mutational burden; architectures ranged from CNNs to MIL and transformers, with heterogeneity limiting cross-study comparisons and validation. Standardized multicenter work is needed.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/artificial-intelligence-for-molecular-biomarker-identification-in-gastrointestinal-and-hepatobiliary-cancers/353356/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/artificial-intelligence-for-molecular-biomarker-identification-in-gastrointestinal-and-hepatobiliary-cancers/353356.png","ImageObject",300,407,{"name":92,"@type":93},"OmBimo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How were relevant studies selected for the review?","Question",{"text":112,"@type":113},"Studies were systematically identified and screened according to the PRISMA 2020 statement and searched in multiple databases including PubMed, Embase, Web of Science, Scopus, and IEEE Xplore.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What kinds of targets and biomarkers were most commonly investigated?",{"text":117,"@type":113},"Most studies focused on colorectal, gastric, liver, and pancreatic cancers, frequently targeting microsatellite instability, mutation status, molecular subtypes, and tumor mutational burden.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is direct comparison of AI model performance across studies difficult?",{"text":121,"@type":113},"Direct comparison is challenging due to substantial heterogeneity in datasets, model architectures, and validation strategies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353356,1790350178,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":24,"preview_urls":146},962090893581,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Review  \nArtificial Intelligence for Molecular Biomarker Identification in Gastrointestinal and Hepatobiliary Cancers  \nHyun-Jong Jang 1, Kwangil Yim 2 and Sung Hak Lee 3, *  \nAcademic Editor: Rafael Parra-Medina  \nReceived: 30 June 2026  \nRevised: 21 July 2026  \nAccepted: 1 August 2026  \nPublished: 3 August 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Physiology, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea; [hjjang@catholic.ac.kr](hjjang@catholic.ac.kr)  \n2 Department of Hospital Pathology, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu 11765, Republic of Korea; [kangse_manse@catholic.ac.kr](kangse_manse@catholic.ac.kr)  \n3 Department of Hospital Pathology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea  \n* [Correspondence: hakjjang@catholic.ac.kr](Correspondence: hakjjang@catholic.ac.kr)  \nAbstract  \nArtificial intelligence (AI) has emerged as a promising tool for inferring molecular biomarkers directly from digitized histopathologic slides. However, the current evidence in gastrointestinal and hepatobiliary cancers remains fragmented across tumor types and biomarker categories. Relevant studies were systematically identified and screened according to the PRISMA 2020 statement. PubMed, Embase, Web of Science Core Collection, Scopus, and IEEE Xplore were searched from 1 January 2015 to the date of search. Eligible studies involved gastrointestinal or hepatobiliary malignancies, used histopathology images, applied AI-based methods, and reported molecular biomarker prediction or inference. A total of 110 studies were included. Most studies focused on colorectal, gastric, liver, and pancreatic cancers, with microsatellite instability, mutation status, molecular subtypes, and tumor mutational burden being the most commonly investigated targets. Model architectures evolved from conventional convolutional neural networks to multiple-instance learning and transformer-based methods. While many studies reported promising predictive performance, direct comparison across studies remained challenging because of substantial heterogeneity in datasets, model architectures, and validation strategies. AIbased molecular biomarker identification from pathologic slides shows substantial promise in gastrointestinal and hepatobiliary cancers, but current evidence is constrained by heterogeneity and limited validation. Standardized, multicenter studies are needed before routine clinical implementation.  \nKeywords: artificial intelligence; deep learning; digital pathology; gastrointestinal cancer; hepatobiliary cancer; molecular biomarker; precision oncology; whole-slide image  \n1. Introduction  \nGastrointestinal and hepatobiliary cancers, including colorectal, gastric, hepatocellular, pancreatic, and biliary tract malignancies, represent a major global health burden and are among the leading causes of cancer-related morbidity and mortality worldwide [1] . These tumors exhibit substantial biological heterogeneity, and molecular characterization has become increasingly essential for diagnosis, prognostication, and therapeutic decision-making [2,3] . The identification of molecular biomarkers—such as gene mutations, microsatellite instability (MSI), gene expression signatures, and molecular subtypes—plays a central role in precision oncology, guiding targeted therapies and immunotherapy  \nstrategies [4] . Consequently, accurate and timely molecular characterization has become an integral component of contemporary cancer management.  \nDespite their clinical importance, conventional approaches for molecular biomarker assessment rely on techniques such as next-generation sequencing (NGS), polymerase chain reaction (PCR)","cbCaigwx0kepHieo","https://ap.wps.com/l/cbCaigwx0kepHieo","pdf",640933,43,"English","# Abstract\n# Introduction\n## Clinical need for molecular biomarker assessment\n## Limitations of conventional assays\n## Digital pathology and whole-slide images\n## AI and deep learning approaches\n## Prior studies predicting molecular biomarkers","[{\"question\":\"How were relevant studies selected for the review?\",\"answer\":\"Studies were systematically identified and screened according to the PRISMA 2020 statement and searched in multiple databases including PubMed, Embase, Web of Science, Scopus, and IEEE Xplore.\"},{\"question\":\"What kinds of targets and biomarkers were most commonly investigated?\",\"answer\":\"Most studies focused on colorectal, gastric, liver, and pancreatic cancers, frequently targeting microsatellite instability, mutation status, molecular subtypes, and tumor mutational burden.\"},{\"question\":\"Why is direct comparison of AI model performance across studies difficult?\",\"answer\":\"Direct comparison is challenging due to substantial heterogeneity in datasets, model architectures, and validation strategies.\"}]","Artificial Intelligence for Molecular Biomarker Identification in Gastrointestinal and Hepatobiliary Cancers | PDF",1790104874,108,[147,151,155,159,163],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b7c10598bcf811097ec90e41b7d8b1b6.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4c9f17cb3614a8291bb9a1973427988f.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/245ba7ca8d86c83653bdcb0118fcfe3c.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8b249531848ae5e9430f8582e4f0f9b0.webp",980,1385,{"page_no":24,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e10dbb954dfa6efbea3e989036b34105.webp",979,1384]